An observational study in COVID19 and Thromboembolism, sponsored by Jessa Hospital. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-19.
Sponsored by Jessa Hospital · Observational
The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.
Background Patients admitted to the Intensive Care Unit (ICU) are known to be at risk for thrombo-embolic events. Virchow's triad describes the major risk factors in three categories: venous stasis, vessel injury and activation of blood coagulation. A prolonged mechanical ventilation together with the hemodynamic effects of this ventilation with a high positive and expiratory pressure (PEEP), the presence of central venous catheters, the immobilization of these patients and the presence of obesity or other comorbidities can attribute to the occurrence of a deep venous thrombosis (DVT) in patients admitted at ICU. The incidence of DVT during ICU stay has been reported between 5 and 15%.
On the 13th of March, the first COVID-19 patient was admitted at the ICU at the Jessa Hospital. Within a few days, the admissions at our COVID-19 unit grew exponential. In these difficult time, research concerning COVID-19 has been performed indicating the COVID-19 virus induces a hyper-inflammatory state. It has been suggested that systemic inflammation induces endothelial injury. This will activate the coagulation cascade and impair fibrinolysis with disruption of endothelial barrier, and loss of physiologic antithrombotic factors which may elevated the risk for DVTs significantly. Up to now, there is still no causal treatment for COVID-19. The current management of COVID-19 is mainly supportive i.e. a prolonged inflammatory status and a prolonged risk for VTE.
We have shown in a previous cross sectional study that the prevalence of deep venous thrombosis (DVT) in critically ill ICU patients with COVID-19 treated with a prophylactic dose of low molecular weight heparin (LMWH) is more than 60% (submitted manuscript). Consequently, the risk of VTE complications in this patient group is very high. In the light of these findings, an intensified thromboprofylaxis protocol was applied in critically ill ICU patients with COVID-19 at our ICU units since 31st of March 2020.
Aim The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.
Design This is a retrospective, longitudinal, before-after controlled study investigating the mortality, the incidence of DVT and the incidence of kidney and liver failure in COVID-19 patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol.
Outcome measures The primary endpoint of this retrospective study is to investigate the mortality in critically ill ICU patients before and after the implementation of the intensified thromboprofylaxis protocol in our hospital.
Secondary endpoints are the incidence of DVTs with the number and locations of these thromboses, the incidence of kidney failure and the incidence of liver failure in COVID-19 patients admitted to the ICU before and after the implementation of the thromboprofylaxis protocol.
Additional data collection
Additional collected parameters are listed below and are collected as a standard-of-care in our hospital:
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 72 is below the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Jessa Hospital is the lead sponsor of 85 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.
Exclusion Criteria:
All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis
Other: standard protocol
On March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented. This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
Other: thromboprofylaxis protocol
This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
2 week mortality
mortality was assessed in all COVID 19 patients admitted to the ICU
Time frame: 2 weeks after admission at ICU
incidence of venous thromboembolism
the incidence of venous thromboembolism was evaluated in all COVID 19 patients admitted to the ICU
Time frame: during ICU stay up till 3th of May 2020
1 week mortality
mortality was assessed in all COVID 19 patients admitted to the ICU
Time frame: 1 week after admission at ICU
3 week mortality
mortality was assessed in all COVID 19 patients admitted to the ICU
Time frame: 3 weeks after admission at ICU
1 month mortality
mortality was assessed in all COVID 19 patients admitted to the ICU
Time frame: 1 month after admission at ICU
incidence of kidney failure
incidence of acute kidney failure in all COVID 19 patients admitted to the ICU
Time frame: during ICU stay up till 3th of May 2020
incidence of continuous renal replacement therapy (CRRT)
incidence of continuous renal replacement therapy (CRRT) in all COVID 19 patients admitted to the ICU
Time frame: during ICU stay up till 3th of May 2020
lowest PaO2/FiO2 (P/F) ratio
evaluation of the lowest P/F ratio in all COVID 19 patients admitted to the ICU
Time frame: during ICU stay up till 3th of May 2020
highest Sequential Organ Failure Assessment (SOFA) score
evaluation of the highest SOFA score in all COVID 19 patients admitted to the ICU
Time frame: during ICU stay up till 3th of May 2020
length of stay
evaluation of the length of stay in ICU and hospital of all COVID 19 patients admitted to the ICU
Time frame: during ICU and hospital stay up till 3th of May 2020
highest bilirubin
evaluation of the highest bilirubine level in all COVID 19 patients admitted to the ICU
Time frame: during ICU stay up till 3th of May 2020
highest ( AST
evaluation of the highest AST level in all COVID 19 patients admitted to the ICU
Time frame: during ICU stay up till 3th of May 2020
highest Aspartaat-Amino-Transferase (ALT)
evaluation of the highest ALT level in all COVID 19 patients admitted to the ICU
Time frame: during ICU stay up till 3th of May 2020
Plan to share: No
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jessa Hospital